Recombinant Human Erythropoietin Dose, Serum Adiponectin, and All-Cause Mortality in Patients Beginning Hemodialysis

Hamamatsu University

Status: Completed

Conditions: Hemodialysis

Study type: Observational

Funder types: Other

Identifiers

NCT00457561

19710808

Details and patient eligibility

About

Decreased body fat mass, possibly mediated through the effects of elevated serum adiponectin levels, may be associated with requirements for higher recombinant human erythropoietin doses and a subsequent worse prognosis in patients beginning hemodialysis.

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who started hemodialysis therapy from August 2000 to May 2001 in 11 dialysis centers in the Shizuoka prefecture area, and who survived for more than 3 months after the start of hemodialysis.

Exclusion criteria

• Nothing particular.